Navigation Links
George Mason University researchers target breast cancer in 3 trials
Date:11/1/2012

Fairfax, Va. -- A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

"The bold long-term goal is a short-term oral treatment that prevents breast cancer by killing the precursor cells that initiate breast cancer," says Lance Liotta, co-director of Mason's Center for Applied Proteomics and Molecular Medicine (CAPMM). "And it's looking hopeful."

The PINC trial (Preventing Invasive Neoplasia with Chloroquine) targets ductal carcinoma in situ, or DCIS, the most common type of pre-invasive breast cancer. Chloroquine is a drug given to prevent or treat malaria; it's showing promise in the early phase of the PINC trial.

CAPMM has three ongoing breast cancer research projects, including the PINC trial, which span the full scope of breast cancer's impact on patients.

In the PINC trial, DCIS is the focus. DCIS shows up as white spots in the MRI of a breast. Those white spots are calcifications that may mark the milk ducts where DCIS cells are growing, says Virginia Espina, assistant research professor at CAPMM. Not all DCIS becomes cancer, but all breast cancer goes through the DCIS stage, she says.

If the patient is diagnosed with DCIS after a biopsy, then she can enter the trial, says Espina, adding that the study doesn't interfere with standard medical treatment. Mason researchers are working with Kirsten Edmiston, a surgeon at Inova Fairfax Hospital who recruits the patients and clinically directs the trial.

While patients are waiting between their diagnosis and the surgery, they take chloroquine once a week for four weeks, Espina says.

A significant reduction in the lesion's size is the sought-after outcome, Espina says. The widely prescribed malaria drug chloroquine has few side effects a rare rash is one, Espina says. There could come a day when chloroquine is taken by women worldwide to prevent breast cancer.

"We can imagine that in the future every woman will take chloroquine once a year," Espina says. "Chloroquine kills off the pre-malignant cells that are starting to accumulate. You'd do this periodically as a new type of chemo prevention."

Chloroquine works by stopping autophagy, which is used by cells to survive under stress. "When your cells realize they don't have enough nutrients, they eat themselves," Espina says. "It's a way to make energy when you don't have enough food."

And that's the spot the DCIS cells are in as they pile up in the milk duct. They're not getting enough oxygen and food and are squashed together.

"For all these reasons, they're under stress," Espina says. "When a cell is under stress, it's a life-and-death struggle. They're not just going to die. They're going to do what they can to survive. That's when they use autophagy to stay alive."

Chemotherapy, a common treatment for cancer, can rev up autophagy, Espina says. "A doctor selects a treatment to try to kill the cell, but the cell is trying to survive; it's trying to do what it's programmed to do. We have to find a way to defeat this cellular process."

Chloroquine works like Pepto-Bismol; it alters the cell's digestive process and therefore autophagy. "But the chloroquine doesn't kill the normal cells because the normal cells aren't dependent on autophagy to survive," Espina says.

The second CAPMM study on breast cancer is funded by the Side-Out Foundation. Researchers are developing individualized treatment for women with metastatic breast cancer. These advanced tumors have spread to other organs, such as the liver, brain and bone, and have limited response to conventional therapies. Standard chemotherapy failed the 25 women Mason has worked with to pinpoint more effective treatments, says Mariaelena Pierobon, CAPMM assistant research professor.

Pierobon is using technology created by Liotta and Emanuel "Chip" Petricoin III to identify which drug targets are activated within each patient tumor. Pierobon's team is building on the promise of personalized medicine by focusing on the molecular profile of the metastatic lesions.

"We hope that by providing physicians with detailed information on the mechanisms that are driving our patients' tumors, we can facilitate the selection of the most appropriate treatment," Pierobon says. "We are trying to guide that decision by using the cutting-edge molecular technologies that were created in our laboratory to select among the FDA-approved drugs that might be the most promising for each patient."

In this approach, patients don't have to wait for new drugs to be developed. "By using drugs that are already approved, you don't have to study toxicity. That's a huge advantage," Pierobon says.

The third study is the I-SPY 2 TRIAL in which CAPMM researcher Julia Wulfkuhle is leading molecular profiling efforts developed uniquely in the Mason laboratory for women with stage II/III breast cancer. The FDA singled out I-SPY 2 as a leading trial design for accelerated drug approval.

The Side-Out Foundation raised $370,000 through volleyball tournaments to fund the metastatic breast cancer trial. The Side-Out Foundation is sponsoring the ongoing CAPMM research studies on the I-SPY 2 TRIAL through the FNIH Foundation for the National Institutes of Health. The Department of Defense Breast Cancer Research Project is funding the majority of the $2.1 million, three-year PINC grant, which started two years ago.


'/>"/>

Contact: Michele McDonald
mmcdon15@gmu.edu
703-993-8781
George Mason University
Source:Eurekalert

Related medicine news :

1. James George, MD: 2012 ASH Wallace H. Coulter Award for Lifetime Achievement in Hematology
2. Georgetown physician leads national resveratrol study for Alzheimers disease
3. Research prizes from the Carlsberg Foundation to researchers from University of Copenhagen
4. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
5. Mercyhurst University presents new research on managing spinal injuries to NFL
6. NTU and University of Warwick boost brainpower in global neuroscience research
7. CDC funds Wayne State University research to understand, prevent teen dating violence
8. Wayne State University researcher recognized by American Psychological Association
9. University of Minnesota chemist named 1 of Popular Sciences Brilliant 10
10. University of Maryland study: Neonatal heart stem cells may help mend kids broken hearts
11. Aarhus University to inaugurate the ultimate source of light:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World ... military munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, ... and silly dog who lives his life to the fullest, as God intended. “The ... author Patti Holmgren, a mother and grandmother pursuing her passion for writing, especially about ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... NJ (PRWEB) , ... March 23, 2017 , ... ... Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be an ... hours of relevant, practical instruction in the management of chronic pain. , Oklahoma ...
(Date:3/23/2017)... ... 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play in ... minimum two times a day that dentists recommend. The ramifications of improper oral upkeep go ... and adults missing 164 million hours of work each year due to dental issues. That ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017  GenomeDx Biosciences today announced that six ... Decipher® Prostate Cancer Classifier tests will be presented at ... (EAU) Congress held March 24 to 28, 2017 in ... Congress is Europe,s largest urological ... the urological field. The abstract titled "Muscle ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... Mar 24, 2017 The Board of Directors ... Annual Report 2016 including the complete 2016 Annual Accounts with ... on Nordic Nanovector,s website in the section Investor Relations/Reports and ... ... Tone Kvåle, Chief Financial Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com ...
Breaking Medicine Technology: